Publications

Research outputs, reports, policy briefs and knowledge products from KIU scholars and partners.

2023 School of Allied Health Sciences Journal of Biomedical Sciences

An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis

Emmanuel Ifeanyi Obeagu1*, Emmanuel Muhimbura2, Byamungu Pahari Kagenderezo3, Onyekachi Splendid Uwakwe1, Sarah Nakyeyune4 and Getrude Uzoma Obeagu1

Sickle cell disease has been described by many scholars as a chronic inflammatorydisease which is linked to many factors such as endothelial destruction,increased synthesis of reactive oxygen specie, haemolysis, increased synthesisof pro inflammatory cytokines among others. Inflammatory process play a majorfunction in the activation of acute painful vaso-occlusion crisis that forms the mainreason for the hospitalization of patients with sickle cell anaemia. Inflammatoryprocesses, are key components of several complications of the disease includingautosplenectomy, acute chest syndrome, pulmonary hypertension, leg ulcer,nephropathy and stroke and also ultimately initiates painful vaso-occlusionepisodes that characterize Sickle Cell Disease. This study titled “Update onInterferon Gamma and C Reactive Proteins in Sickle Cell Anaemia in Crises, aimsat finding out the recent updates on interferon gamma; a pro-inflammatorycytokine that plays a central role in inflammation and auto-immunity, and CRP;an acute phase protein used as a marker of inflammation in sickle cell anaemiapatients in crisis. A lot of search engines were consulted in the course of writingthis review such as scopus, Pubmed Central, Web of Science, Semantics, GoogleScholar, Researchgate, Academia Edu, etc. Previous studies have suggested thatlevels of pro-inflammatory cytokines vary between steady-state and crisis statesin SCA patients, hypothesized to help monitor clinical progression of the disease.. Newer therapies that target pathways downstream of the sickle are consideredbetter options. This knowledge may have implications for the development of newtreatments for sickle cell disease